Cencora (COR) has had an eventful stretch with various investment firms adjusting their stakes in the company. The biotech firm resolved a significant litigation overhang through a proposed $111 million settlement, sparking a change in investor sentiment and narrative. This move, coupled with high-profile appointment of D. Mark Durcan as Board Chairman, known for his tech innovation experience, and amending credit agreements for enhanced flexibility, has attracted interest from investment entities.
Ascent Group LLC,
Integrated Wealth Concepts LLC, and
Meiji Yasuda Life Insurance Co among others, have increased their holdings. Notably,
Integrity Alliance LLC, Blue Rock Wealth Management LLC, and
Caxton Associates LLP have taken new impressive positions in Cencora. While some investment firms like Vident Advisory LLC, USS Investment Management Ltd, and Royal Bank of Canada have marginally trimmed their holdings, the overall investment milieu for Cencora is bullish. Investors who put faith in Cencora five years ago have seen a 234% return. Their Q2 earnings were in line with expectations and company's earnings are expected to grow. Their strong demand for specialty drugs allowed them to raise their annual profit forecast. The consensus recommendation from brokerages is “Moderate Buy”.
Cencora COR News Analytics from Tue, 11 Mar 2025 07:00:00 GMT to Sun, 14 Sep 2025 00:41:47 GMT -
Rating 8
- Innovation 5
- Information 7
- Rumor 4
